Browse by author
Lookup NU author(s): Emeritus Professor Alan Craft,
Professor Archibald Malcolm
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: to investigate the possibility that the substitution of ifosfamide for cyclophosphamide therapy for Ewing's sarcoma will improve survival over that seen in the first United Kingdom Children's Cancer Study Group (UKCCSG) Ewing's tumor study (ET-I). Patients and Methods: Between 1987 and 1993, 243 patients (138 men or boys) were entered onto the study The median age was 13.5 years (range, 1.5 to 27 years). The median follow-up was 58 months. Chemotherapy included four courses of vincristine 2 mg/m(2); ifosfamide 9 g/m(2); and doxorubicin 60 mg/m(2) administered every 3 weeks. Treatment of the primary tumor was with surgery and/or radiotherapy followed by ifosfamide 6 g/m(2); doxorubicin 60 mg/m(2); and vincristine 2 mg/m(2); with actinomycin D 1.5 mg/m(2) substituted for doxorubicin after a total dose of 420 mg/m(2). Results: Two hundred one patients had no metastases, One hundred eighteen patients had tumors of the axial skeleton and 125 patients had limb primary tumors. The major toxicities were hematologic and infective, but there were no toxic deaths. The overall survival rate was 62% (95% confidence interval [CI], 56 to 69) and relapse-free survival (RFS) 56% (95% CI, 49 to 62). For those with no metastases at diagnosis, the RFS rate was 62% and for those with metastases, 23%. Multivariate analysis showed age and site to have a significant effect on RFS. Pelvic sites had the worst RFS rate of 41%; other axial sites, 55%; and extremity tumors, 73%, Age younger than 10 years had an RFS rate of 86% versus 55% for older patients. The local relapse rate for axial tumors was 20% and for limb primary tumors was 2.4%, Conclusion: The 5-year survival rate of 62% is improved compared with the 44% survival rate achieved in ET-l, This is probably caused by the use of higher doses of ifosfamide compared with relatively low doses of cyclophosphamide in ET-1. (C) 1998 by American Society of Clinical Oncology.
Author(s): Craft, A. W., Cotterill, S. J., Malcolm, A. J., Spooner, D., Grimer, R., Souhami, R., Imeson, J., Lewis, I.
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Oncology
Print publication date: 01/11/1998
ISSN (print): 0732-183X
ISSN (electronic): 1527-7755
PubMed id: 9817284